Cadila Healthcare has received tentative approval from the USFDA to market Carvedilol tablets - 3.125 mg, 6.25 mg, 12.5 mg and 25 mg - in the US market.According to a release issued by Cadila to the BSE today, the drug falls in the cardiovascular segment, and current sales of Carvedilol tablets in the US market, as per NDC Health, is estimated at $1.24 billion.
